The European Medicines Agency (EMA) has identified severe allergic reactions as a potential side effect of the Novavax vaccine. (Schematic) Figure: Retrieved from Novavax Twitter
The Wuhan pneumonia epidemic continues to spread around the world, and countries are still conducting vaccination operations. The European Medicines Agency (EMA) today determined that severe allergic reactions are a potential side effect of Novavax Inc’s vaccine. The Novavax vaccine requires two doses given three weeks apart, using a more traditional technique than the mRNA vaccine. Vaccines contain parts of the virus that elicit an immune response, which is how many other common vaccines are developed.
Reuters reported that the European Medicines Agency will also update the vaccine product information, adding skin paresthesia or reduction as a new side effect. Only 250,000 doses of the Novavax vaccine, known in Europe as Nuvaxovid, were launched in December, according to the European Centre for Disease Prevention and Control.
Novavax is a sub-unit protein vaccine, suitable for adults over 18 years old. The dosage is 2 doses of 0.5 ml (containing 5 mg of SARS-CoV-2 spike protein), and the interval between 2 doses is 3 weeks. U.S. regulators approved the Novavax vaccine yesterday, with a product label warning against people with a history of allergic reactions to the vaccine’s ingredients. Novavax shares fell today along with the broader market and other makers of a coronavirus vaccine. Novavax stock price fluctuates frequently.
The Novavax vaccine, made by a U.S. company, is available in dozens of countries. The U.S. previously authorized only three COVID-19 vaccines, two of which were developed based on mRNA technology. Novavax hopes its vaccine will attract people who reject Pfizer/BioNTech and Moderna’s vaccines, which use mRNA technology. About 22% of people in the United States have yet to receive a single dose of the Wuhan pneumonia vaccine.
On June 30, 504,000 doses of Novavax vaccine arrived in Taiwan. The Food and Drug Administration approved Novavax for adults over 18 years old to give 2 doses at intervals of more than 3 weeks. After the meeting of experts of the Advisory Committee on Vaccination (ACIP), Novavax can be administered. The first to fourth doses are provided to people over the age of 18, and they can be alternately vaccinated with other brands. Appointments are currently open and will be launched in various counties and cities one after another.